Back
20 Feb 2026
Sumitomo Pharma shares plunge nearly 16% despite greenlight for Parkinson's treatment
Summary
Sumitomo Pharma shares fell 15.60% despite government endorsement of its iPS cell-based therapy for Parkinson’s and heart disease. The company’s stock, which surged over 300% in 2025, is expected to see limited profit contribution in the near term.